- This line was added.
- This line was removed.
- Formatting was changed.
The RIDER Lung CT collection was constructed as part of a study to evaluate the variability of tumor unidimensional, bidimensional, and volumetric measurements on same-day repeat computed tomographic (CT) scans in patients with non–small cell lung cancer.
Thirty-two patients with non–small cell lung cancer, each of whom underwent two CT scans of the chest within 15 minutes by using the same imaging protocol, were included in this study. Three radiologists independently measured the two greatest diameters of each lesion on both scans and, during another session, measured the same tumors on the first scan. In a separate analysis, computer software was applied to assist in the calculation of the two greatest diameters and the volume of each lesion on both scans. Concordance correlation coefficients (CCCs) and Bland-Altman plots were used to assess the agreements between the measurements of the two repeat scans (reproducibility) and between the two repeat readings of the same scan (repeatability).
About the RIDER project
The Reference Image Database to Evaluate Therapy Response (RIDER) is a targeted data collection used to generate an initial consensus on how to harmonize data collection and analysis for quantitative imaging methods applied to measure the response to drug or radiation therapy. The National Cancer Institute (NCI) has exercised a series of contracts with specific academic sites for collection of repeat "coffee break," longitudinal phantom, and patient data for a range of imaging modalities (currently computed tomography [CT] positron emission tomography [PET] CT, dynamic contrast-enhanced magnetic resonance imaging [DCE MRI], diffusion-weighted [DW] MRI) and organ sites (currently lung, breast, and neuro). The methods for data collection, analysis, and results are described in the new Combined RIDER White Paper Report (Sept 2008):
The long term goal is to provide a resource to permit harmonized methods for data collection and analysis across different commercial imaging platforms to support multi-site clinical trials, using imaging as a biomarker for therapy response. Thus, the database should permit an objective comparison of methods for data collection and analysis as a national and international resource as described in the first RIDER white paper report (2006):
ISMRM 2009 poster demonstrates how each of the "coffee break" exams were used as an estimate of each patient's null hypothesis, i.e. distribution associated with no change, and thus supports the estimate of the nulls 97.5 percentile for subsequent estimation of early response to neoadjuvant chemotherapy on an individual patient basis.